Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Herrington

Hematology & Oncology Hattiesburg, MS Medical Doctor

NPI 1730192907 CMS profile 78958

301 S 28Th Ave, Hattiesburg, MS 39401

Open in the dashboard

General payments

$14,253

741 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Herrington of Hattiesburg, MS is reported in the CMS Open Payments database as having received $14,253 across 741 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,932 136
2024 General $2,662 128
2023 General $2,456 125
2022 General $2,063 113
2021 General $1,222 66
2020 General $804 43
2019 General $2,114 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Herrington
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to James Herrington were reported at $2,932. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year James Herrington Hematology & Oncology median Middle half National median
2019 $2,114 $529 $121–$2,516 $163
2020 $804 $339 $82–$2,213 $114
2021 $1,222 $263 $49–$1,965 $132
2022 $2,063 $416 $103–$2,395 $149
2023 $2,456 $542 $125–$2,646 $160
2024 $2,662 $692 $141–$3,008 $164
2025 $2,932 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,002 50 payments
  2. E.R. Squibb & Sons, L.L.C. $803 42 payments
  3. Novartis Pharmaceuticals Corporation $703 40 payments
  4. Incyte Corporation $691 34 payments
  5. Genentech USA, Inc. $679 37 payments
  6. Pfizer Inc. $651 42 payments
  7. AstraZeneca Pharmaceuticals LP $623 33 payments
  8. Seattle Genetics, Inc. $564 21 payments
  9. Daiichi Sankyo Inc. $474 20 payments
  10. Astellas Pharma US Inc $465 26 payments
  11. Other $7,597 396 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,653 730 payments
  2. Education $600 11 payments
Products named General payments · program years 2019–2025
  1. OPDIVO $637 36 payments
  2. XTANDI $456 27 payments
  3. KEYTRUDA $454 21 payments
  4. JAKAFI $369 22 payments
  5. REBLOZYL $354 15 payments
  6. ENHERTU $339 14 payments
  7. IMBRUVICA $335 18 payments
  8. MONJUVI $293 15 payments
  9. DARZALEX $289 20 payments
  10. SARCLISA $281 14 payments
  11. Other $12,022 648 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

741 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record